| Autor: |
Kirichenko YY; Sechenov First Moscow State Medical University., Kulagina TY; Academician Petrovsky Russian Research Center of Surgery., Zhigulina OA; Academician Petrovsky Russian Research Center of Surgery., Ilgisonis IS; Sechenov First Moscow State Medical University., Belenkov YN; Sechenov First Moscow State Medical University. |
| Jazyk: |
ruština |
| Zdroj: |
Kardiologiia [Kardiologiia] 2024 May 31; Vol. 64 (5), pp. 33-38. Date of Electronic Publication: 2024 May 31. |
| DOI: |
10.18087/cardio.2024.5.n2661 |
| Abstrakt: |
Significant advances in timely diagnosis and modern antitumor therapy have led to a considerable increase in the survival rate of cancer patients. On the other hand, the incidence of cardiovascular (CV) diseases and their complications is increasingly growing, including due to side effects of anticancer drugs. CV complications are the most common cause of non-oncological death of cancer patients. The development of polychemotherapy-induced arterial hypertension (AH) is closely associated with the use of certain groups of drugs, for example, inhibitors of vascular endothelial growth factor (iVEGF). Such AH is generally dose-dependent and reversible after interruption or termination of treatment. However, systemic AH, regardless of its genesis, is one of the key risk factors for many CV events (myocardial infarction, stroke, heart failure, arrhythmias) and kidney disease. Therefore, thorough blood pressure monitoring and its timely and adequate correction if needed are indicated when using certain groups of chemotherapy drugs. This article describes a clinical follow-up of a patient with induced AH associated with the iVEGF antitumor therapy for advanced uterine cancer with a rapid development of left ventricular myocardial dysfunction. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
